Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Cleared to Begin Phase I/II Trial of Ocular Hypertension Drug

Premium

Sylentis said this week that it has received clearance from Spanish regulators to begin a second phase I/II trial of its siRNA-based ocular hypertension drug SYL040012.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Earlier this summer, the company completed a phase Ia trial, finding the agent to be safe and well-tolerated in healthy volunteers (GSN 7/8/2010).

The new trial will enroll patients with elevated intraocular pressure. Sylentis aims to develop SYL040012 as a glaucoma treatment.